Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
90.22 EUR | +2.44% |
|
0.00% | -1.59% |
Jun. 27 | CAC40: caution prevails ahead of crucial deadlines | CF |
Jun. 27 | CAC40: consolidates solo, OAT/Bund spread widens to 81Pb | CF |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The company returns high margins, thereby supporting business profitability.
- The company is in a robust financial situation considering its net cash and margin position.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The opinion of analysts covering the stock has improved over the past four months.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
Weaknesses
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-1.59% | 120B | - | ||
+56.50% | 819B | C+ | ||
-6.48% | 351B | C+ | ||
+18.31% | 329B | B- | ||
+9.35% | 298B | C+ | ||
+16.57% | 242B | B+ | ||
+2.04% | 225B | A+ | ||
+13.31% | 217B | B- | ||
+8.35% | 168B | C+ | ||
-2.94% | 158B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- SAN Stock
- 1SAN Stock
- Ratings Sanofi